Skip to main content

MECANISMOS MOLECULARES IMPLICADOS EN LA MODULACION DE LA MEMORIA DEPENDIENTE DE HIPOCAMPO POR EL SISTEMA ENDOCANNABINOIDE

SAF2009-07309

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2009
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a critical role in the amnesic-like effects of cannabinoids. In this study, we summarize the cellular and molecular mechanisms reported in the modulation of cognitive function by the endocannabinoid system., EP is a recipient of an EMBO Fellowship with the support of European Commission (EMBOCOFUND2010, GA-2010-267146) and Marie Curie Actions. AB-G is a recipient of a predoctoral fellowship, Spanish Ministry of Education and Culture. This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Spanish Ministry of Science and Innovation (#SAF2009-07309 to AO and/n#SAF2011-29864 to RM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR-2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure

  • Cutando Ruiz, Laura, 1985-
  • Busquets Garcia, Arnau, 1985-
  • Puighermanal Puigvert, Emma, 1983-
  • Gomis González, Maria, 1988-
  • Delgado García, José María
  • Gruart, Agnès
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Chronic cannabis exposure can lead to cerebellar dysfunction in humans, but the neurobiological mechanisms involved remain incompletely understood. Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1β. This neuroinflammatory phenotype correlated with deficits in cerebellar conditioned learning and fine motor coordination. The neuroinflammatory phenotype was readily detectable in the cerebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice lacking CB1R in the cerebellar parallel fibers, suggesting that CB1R downregulation in the cerebellar molecular layer plays a key role in THC-induced cerebellar deficits. Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased under neuroinflammatory conditions in activated CD11b-positive microglial cells. Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1β receptor signaling prevented the deficits in cerebellar function in Cb1(-/-) and THC-withdrawn mice. Our results suggest that cerebellar microglial activation plays a crucial role in the cerebellar deficits induced by repeated cannabis exposure., This study was supported by grants from the Ministerio de Ciencia e Innovación (BFU2008-03390, to A. Gruart; BFU2008-00899, to J.M. Delgado-García; SAF2007-64062 and SAF2011-29864, to R. Maldonado; and SAF2009-07309 and BFU2012-33500, to A. Ozaita); the European Commission (PHECOMP, LSHM-CT-2007-037669, to R. Maldonado); the Instituto de Salud Carlos III (RTA-RETICS, RD06/001/001, to R. Maldonado); the Generalitat de Catalunya (SGR2009-SGR00731, to R. Maldonado); the Fundació La Marató de TV3 (090910, to A. Ozaita); and the ICREA Academia (to R. Maldonado). Partial support from the EU FEDER funds is also acknowledged.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Targeting the endocannabinoid system in the treatment of fragile X syndrome

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Guegan, Thomas, 1983-
  • Agustín Pavón, Carmen
  • Pastor, Antonio
  • Mato, Susana
  • Pérez Samartín, A.
  • Matute, Carlos
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) signaling seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 activation, is altered in several brain areas of Fmr1 knockout mice. We found that CB1R blockade in male Fmr1 knockout (Fmr1(-/y)) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS., This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO, #SAF2011-29864 to RM and SAF2010-21547 to CM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats)/nAcademia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure

  • Cutando Ruiz, Laura, 1985-
  • Busquets Garcia, Arnau, 1985-
  • Puighermanal Puigvert, Emma, 1983-
  • Gomis González, Maria, 1988-
  • Delgado García, José María
  • Gruart, Agnès
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Chronic cannabis exposure can lead to cerebellar dysfunction in humans, but the neurobiological mechanisms involved remain incompletely understood. Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1β. This neuroinflammatory phenotype correlated with deficits in cerebellar conditioned learning and fine motor coordination. The neuroinflammatory phenotype was readily detectable in the cerebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice lacking CB1R in the cerebellar parallel fibers, suggesting that CB1R downregulation in the cerebellar molecular layer plays a key role in THC-induced cerebellar deficits. Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased under neuroinflammatory conditions in activated CD11b-positive microglial cells. Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1β receptor signaling prevented the deficits in cerebellar function in Cb1(-/-) and THC-withdrawn mice. Our results suggest that cerebellar microglial activation plays a crucial role in the cerebellar deficits induced by repeated cannabis exposure., This study was supported by grants from the Ministerio de Ciencia e Innovación (BFU2008-03390, to A. Gruart; BFU2008-00899, to J.M. Delgado-García; SAF2007-64062 and SAF2011-29864, to R. Maldonado; and SAF2009-07309 and BFU2012-33500, to A. Ozaita); the European Commission (PHECOMP, LSHM-CT-2007-037669, to R. Maldonado); the Instituto de Salud Carlos III (RTA-RETICS, RD06/001/001, to R. Maldonado); the Generalitat de Catalunya (SGR2009-SGR00731, to R. Maldonado); the Fundació La Marató de TV3 (090910, to A. Ozaita); and the ICREA Academia (to R. Maldonado). Partial support from the EU FEDER funds is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting the endocannabinoid system in the treatment of fragile X syndrome

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Guegan, Thomas, 1983-
  • Agustín Pavón, Carmen
  • Pastor, Antonio
  • Mato, Susana
  • Pérez Samartín, A.
  • Matute, Carlos
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) signaling seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 activation, is altered in several brain areas of Fmr1 knockout mice. We found that CB1R blockade in male Fmr1 knockout (Fmr1(-/y)) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS., This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO, #SAF2011-29864 to RM and SAF2010-21547 to CM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats)/nAcademia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a critical role in the amnesic-like effects of cannabinoids. In this study, we summarize the cellular and molecular mechanisms reported in the modulation of cognitive function by the endocannabinoid system., EP is a recipient of an EMBO Fellowship with the support of European Commission (EMBOCOFUND2010, GA-2010-267146) and Marie Curie Actions. AB-G is a recipient of a predoctoral fellowship, Spanish Ministry of Education and Culture. This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Spanish Ministry of Science and Innovation (#SAF2009-07309 to AO and/n#SAF2011-29864 to RM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR-2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM